Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Brian J BallShukaib ArslanPaul KollerDat NgoMichelle AfkhamiAmandeep SalhotraMonzr M Al MalkiAhmed AribiHaris AliKaramjeet SandhuSalman OtoukeshIdoroenyi AmanamHoda Z PourhassanAndrew S ArtzPeter CurtinAnthony SteinRyotaro NakamuraGuido MarcucciEileen SmithVinod A PullarkatIbrahim AldossPublished in: Leukemia & lymphoma (2022)